期刊文献+

胰高血糖素样肽-1对糖尿病大鼠胰岛素敏感性及心肌微血管的保护作用 被引量:1

下载PDF
导出
摘要 目的探讨胰高血糖素样肽-1对糖尿病大鼠胰岛素敏感性及心肌微血管的保护作用。方法 24只成年雄性SD大鼠随机分为正常对照(NC)组(n=8)、2型糖尿病(T2DM)组(n=8)、T2DM加胰高血糖素样肽-1(GLP-1)干预组(n=8),对比GLP-1对各组大鼠葡萄糖输注率、胰岛素浓度的影响以及三组大鼠心肌微血管完整性和通透性。结果各组大鼠的葡萄糖输注率均于60.0 min时趋向于基本稳定状态,此前T2DM+GLP-1组和T2DM组的输注率增长趋势低于NC组;在120.0 min后T2DM组葡萄糖输注率与NC组相比下降幅度约为53.0%(P<0.05);与NC组相比,T2DM+GLP-1组葡萄糖输注率有所降低,但差异无统计学意义(P>0.05);与T2DM组相比,T2DM+GLP-1组葡萄糖输注率上升约为50.8%(P<0.05),T2DM+GLP-1组葡萄糖输注率有所增高,但未上升至正常水平;实验开始时各组大鼠胰岛素水平均呈现持续上升趋势,三组大鼠间胰岛素浓度增加趋势及同一时间点胰岛素浓度均无统计学差异(P>0.05);NC组心肌微血管铸型较为平滑,且未出现明显的凹凸不平,表明无破坏发生,T2DM组心肌微血管铸型出现显著凹凸不平现象,且内皮连接完整性较差,T2DM+GLP-1组心肌微血管内皮细胞连接完整度明显优于T2DM组;NC组心肌微血管内皮细胞连接完整,未出现镧颗粒进入基底膜现象,T2DM组镧颗粒可轻易透过内皮细胞进入基底膜及其周边组织,T2DM+GLP-1组仅有少量镧颗粒进入基底膜。结论 GLP-1可改善糖尿病患者胰岛素敏感性,并对心肌微血管产生保护作用。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第21期5267-5269,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献5

二级参考文献79

  • 1Bi Y, Zeng L, Zhu D, et al. Association of beta-cell function and insulin sensitivity with fasting and 2-h plasma glucose in a large Chinese population[ J]. Diabetes Obes Metab, 2012,14 (2) : 174-180.
  • 2Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta ceils [ J]. Diabetologia, 2007,50 ( 6 ) : 1304-1314.
  • 3Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion[J]. Circ Res, 2013,113(2) :167-175.
  • 4Shimodaira M, Niwa T, Nakajima K, et al. Impact of serum triglyceride and high density lipoprotein cholesterol levels on early-phase insulin secretion in normoglycemic and prediabetic subjects[ J]. Diabetes Metab J, 2014,38(4) :294-301.
  • 5Deacon CF, Ahren B. Physiology of incretins in health and disease [ J ]. Rev Diabet Stud, 2011,8 ( 3 ) : 293-306.
  • 6Kuhre RE, Gribble FM, Hartmann B, et al. Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans [ J ]. Am J Physiol Gastrointest Liver Physiol, 2014,306 (7) : G622-G630.
  • 7Martin JH, Deacon CF, Gorrell MD, et al. Incretin-based therapies-- review of the physiology, pharmacology and emerging clinical experience[J]. Intern Med J, 2011,41 (4) :299-307.
  • 8Nauek MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications[ J]. Am J Med, 2011, 124( 1 Suppl) :S3-S18.
  • 9Marathe CS, Rayner CK, Bound M, et al. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes [ J]. Diabetes, 2014,63 (8) :2668-2675.
  • 10Deacon CF, Nauek MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide[ J]. J Clin Endoerinol Metab, 2000,85 ( 10 ) : 3575-3581.

共引文献24

同被引文献14

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部